
RETATRUTIDE & KNEE OA IN OBESE PATIENTS. Obesity is the most prevalent disease in the world. It's a risk factor for a host of negative outcomes, including knee osteoarthritis (patients with obesity have a 60% lifetime risk of knee OA). Weight loss drugs have ballooned in popularity in recent years as a result. Retatrutide -- an experimental, triple-receptor agonist developed by Eli Lilly -- is the latest iteration which has shown considerable promise as a weight loss drug. However, Phase 3 efficacy have been lacking. Until now. The TRIUMPH-1 trial, just released in the NEJM, randomized 2,339 patients with obesity and no diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4, 9, or 12mg) or a placebo for 80 weeks. They found that: 1) Patients on retatrutide lost ~20% more weight than the placebo group. 2) Among participants with knee OA, there were pain reductions as high as 61.6%. 3) Among those with sleep apnea, the reduction in apnea-hypopnea events was as high as 57.3%. 4) Among pre-diabetic patients, more than 90% reverted to normoglycemia. 5) The most frequently reported adverse events were gastrointestinal in nature. The results demonstrate the potential for this novel weight loss drug to not only reduce obesity -- but also mitigate the downstream consequences. Citation: Jastreboff, Ania M., et al. "Retatrutide, a triple hormone receptor agonist, for treatment of obesity." N Engl J Med 395 (2026): 1781-1793.



